Clinical Performance of Two Methods for Detecting Anti SARS-CoV-2 Antibodies

Evaluating the clinical performance of available methods to detect antibodies against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has become a primordial issue in laboratories. The aim this study was evaluate two for SARS-CoV-2 detection, an automated Chemiluminescent Immunoassay (CLIA) and immunochromatographic Lateral-Flow Assay (LFA) patients with positive reverse transcription polymerase chain reaction (RT-PCR). Performance CLIA method Positive Agreement (PA) 56.6% Negative (NA) 96,6% IgM PA 85.8%/NA 90,2% IgG. LFA 56.2% NA 100% 95.5% 100 % general agreement IgG better than CLIA. In both methods, significant differences Kappa index are observed when compared. When evaluating data from perspective, we found that detection may not meet expected requirements their utility could lead inappropriate medical decision. findings show immunoassay might be reliable assessing immunological response COVID-19 patients. Our results also confirm measurement helpful, especially epidemiological studies our population. These provide evidence justify